Blonanserin: New Serotonin-Dopamine Antagonist.
- Author:
Won KIM
1
;
Won Myong BAHK
Author Information
1. Department of Psychiatry and Stress Research Institute, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
- Publication Type:Review
- Keywords:
Blonanserin;
Atypical antipsychotics
- MeSH:
Haloperidol;
Japan;
Korea;
Piperazines;
Piperidines;
Prolactin;
Receptor, Serotonin, 5-HT2A;
Receptors, Dopamine D2;
Risperidone;
Schizophrenia;
Serotonin
- From:Korean Journal of Psychopharmacology
2011;22(1):5-14
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Blonanserin is a newly developed agent which is approved for the treatment of schizophrenia in Japan and Korea. This agent has high affinity to dopamine D2 receptor and serotonin 5-HT2A receptor. Blonanserin was as effective as risperidone in the treatment of schizophrenia, and showed greater efficacy in negative symptoms than haloperidol. Blonanserin was well tolerated in both the short- and long-term studies, and the frequency and intensity of EPS is generally similar with risperidone. For other side effects, blonanserine seems to have better safety profiles compared with other atypicals, and showed less prolactin elevation than risperidone. These findings suggest that blonanserin is useful in the treatment of schizophrenia.
